This study evaluates the value of a transcriptomic signature, GemPred, to predict gemcitabine sensitivity in patients with resected pancreatic ductal adenocarcinoma (PDAC). This signature provides evidence of the possibility to uncover and apply clinically phenotyping tools for personalized medicine.
The study demonstrated that patients classified as GemPred+, indicating a high likelihood of gemcitabine response, experienced significantly better disease-free and cancer-specific survival compared to those categorized as GemPred–. GemPred+ patients exhibited similar survival outcomes regardless of whether they received gemcitabine or a more aggressive chemotherapy regimen.
These findings highlight the potential of GemPred and more generally the transcriptome to guides patient treatment decisions, enabling to select the most effective and least toxic therapy for each individual patient.